Biblio Discovery — Demo Discovery Service

25 hasil untuk "Chang, Ching-Fu"

Menampilkan 1–20 · 0,43 detik · RSS

  1. Artikel Jurnal Teks lengkap

    PD-L1 Immunohistochemistry Comparability and Their Correlation with Clinical Characteristics in NSCLC

    Wu, Chiao-En; Chang, Ching-Fu; Kou-Sheng, Liao dkk.

    Anal Cell Pathol (Amst) · 2020 · Inggris · PubMed Central

    BACKGROUND: PD-L1 expression is an important predictive factor of response to therapy with immune checkpoint inhibitors (ICIs). This study was designed to retrospectively analyze the concordance of PD-L1 measurements using three different assays (Dako22C3, Dako28-8, and SP142) in NSCLC patients and…

  2. Artikel Jurnal Teks lengkap

    Systemic Therapy for Gastrointestinal Stromal Tumor: Current Standards and Emerging Challenges

    Huang, Wen-Kuan; Wu, Chiao-En; Wang, Shang-Yu dkk.

    Curr Treat Options Oncol · 2022 · Inggris · PubMed Central

    Gastrointestinal stromal tumor (GIST), though rare, is the most common mesenchymal tumors of the gastrointestinal tract. KIT or PDGFRα mutation plays as an oncogenic driver in the majority of GISTs. Surgical resection is the only curative treatment for localized disease. The discovery of imatinib…

  3. Artikel Jurnal Teks lengkap

    Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study

    Wu, Chiao-En; Chang, Ching-Fu; Huang, Chen-Yang dkk.

    BMC Cancer · 2021 · Inggris · PubMed Central

    …with PS ≥ 2. METHODS: The data for 62 patients who were treated at Linkou Chang Gung Memorial Hospital from January 2010 to August 2019 were retrospectively reviewed. Patients’ clinicopathological features were obtained, and univariate and multivariate analyses were performed to identify possible…

  4. Artikel Jurnal Teks lengkap

    Comparison of Different Tyrosine Kinase Inhibitors for Treatment of Poor Performance Status Patients with EGFR-Mutated Lung Adenocarcinoma

    Wu, Chiao-En; Chang, Ching-Fu; Huang, Chen-Yang dkk.

    Cancers (Basel) · 2022 · Inggris · PubMed Central

    SIMPLE SUMMARY: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are standard treatments in patients with EGFR-mutated lung adenocarcinoma. However, the clinical data regarding EGFR-TKI efficacy in patients with poor performance status (PS ≥ 2) are limited. We reviewed the…

  5. Artikel Jurnal Teks lengkap

    Prognostic Factors for Advanced Pancreatic Cancer Treated with Gemcitabine Plus S-1: Retrospective Analysis and Development of a Prognostic Model

    Chang, Ching-Fu; Huang, Pei-Wei; Chen, Jen-Shi dkk.

    Cancers (Basel) · 2019 · Inggris · PubMed Central

    Gemcitabine plus S-1 (GS) is commonly used to treat advanced pancreatic cancer (APC) in Asia. Few clinical experiments have demonstrated the clinical efficacy of GS in routine clinical practice. We aimed to identify the prognostic factors and develop a prognostic model for survival prediction in…

  6. Artikel Jurnal Teks lengkap

    The impact of BRAF targeting agents in advanced anaplastic thyroid cancer: a multi-institutional retrospective study in Taiwan

    Chang, Ching-Fu; Yang, Ming-Han; Lee, Jih-Hsiang dkk.

    Am J Cancer Res · 2022 · Inggris · PubMed Central

    Anaplastic thyroid cancer (ATC) is a rare but lethal thyroid cancer. Dabrafenib and trametinib has been the standard treatment for the patients with BRAF mutation based on phase II study. This study aimed to exam the impact of dabrafenib and trametinib in ATC patients. ATC patients treated in three…

  7. Artikel Jurnal Teks lengkap

    Risk Stratification Using a Novel Nomogram for 2190 EGFR-Mutant NSCLC Patients Receiving the First or Second Generation EGFR-TKI

    Chang, John Wen-Cheng; Huang, Chen-Yang; Fang, Yueh-Fu dkk.

    Cancers (Basel) · 2022 · Inggris · PubMed Central

    SIMPLE SUMMARY: No comprehensive and simple prognostic model based on pretreatment factors exists for patients with epidermal growth factor receptor mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC) undergoing EGFR-tyrosine kinase inhibitors (EGFR-TKIs). A total of 11 independent…

  8. Artikel Jurnal Teks lengkap

    The survival after discontinuation of EGFR‐TKIs due to intolerable adverse events in patients with EGFR‐mutated non–small cell lung cancer

    Chang, John Wen‐Cheng; Chang, Ching‐Fu; Huang, Chen‐Yang dkk.

    Thorac Cancer · 2022 · Inggris · PubMed Central

    …advanced NSCLC patients treated with EGFR‐TKIs as frontline treatment at Chang Gung Memorial Hospitals from June 2014 to March 2018 were retrospectively reviewed. RESULTS: A total of 2190 patients were enrolled and treated with frontline EGFR‐TKIs. In August 2021, 114 (5.2%) patients experienced…

  9. Artikel Jurnal Teks lengkap

    Epidermal growth factor receptor tyrosine kinase inhibitors for non‐small cell lung cancer harboring uncommon EGFR mutations: Real‐world data from Taiwan

    Chang, John Wen‐Cheng; Huang, Chen‐Yang; Fang, Yueh‐Fu dkk.

    Thorac Cancer · 2022 · Inggris · PubMed Central

    …to four institutions, Linkou, Kaohsiung, Keelung, and Chiayi, of the Chang Gung Memorial Hospital) in Taiwan were retrospectively reviewed. Their clinicopathological characteristics, adverse events (AEs), objective response rate (ORR), disease control rate (DCR), progression‐free survival (PFS)…

  10. Artikel Jurnal Teks lengkap

    Epidermal growth factor receptor tyrosine kinase inhibitors for de novo T790M mutation: A retrospective study of 44 patients

    Chang, John Wen‐Cheng; Huang, Chen‐Yang; Fang, Yueh‐Fu dkk.

    Thorac Cancer · 2022 · Inggris · PubMed Central

    BACKGROUND: This study aimed to evaluate possible treatment strategies for patients with de novo T790M mutation‐positive (T790M+) non‐small‐cell lung cancer (NSCLC). METHODS: Patients diagnosed with de novo T790M+ NSCLC and treated with epidermal growth factor receptor tyrosine kinase inhibitors…

  11. Artikel Jurnal Teks lengkap

    Effectiveness and safety of afatinib, gefitinib, and erlotinib for treatment-naïve elderly patients with epidermal growth factor receptor-mutated advanced non-small-cell lung cancer: a multi-institute retrospective study

    Hung, Ling-Jen; Hsu, Ping-Chih; Yang, Cheng-Ta dkk.

    Aging (Albany NY) · 2024 · Inggris · PubMed Central

    Background: In real-world practice, most patients with lung cancer are diagnosed when they are aged ≥65 years. However, clinical trials tend to lack data for the elderly population. Therefore, we aimed to describe the effectiveness and safety of afatinib, gefitinib, and erlotinib for elderly…

  12. Artikel Jurnal Teks lengkap

    Sequential treatment in advanced non–small cell lung cancer harboring EGFR mutations

    Hsu, Ping-Chih; Chang, John Wen-Cheng; Chang, Ching-Fu dkk.

    Ther Adv Respir Dis · 2022 · Inggris · PubMed Central

    …and second-generation EGFR-TKIs in Linkou, Kaohsiung, Chiayi and Keelung Chang Gung Memorial Hospitals were retrospectively retrieved and analyzed. RESULTS: Until August 2021, among 1943 patients who experienced progressive disease, 526 underwent T790M mutation tests, and their T790M-positive rate…

  13. Artikel Jurnal Teks lengkap

    Genomic landscape and comparative analysis of tissue and liquid-based NGS in Taiwanese anaplastic thyroid carcinoma

    Yeh, Chun-Nan; Lin, Shu-Fu; Wu, Chia-Ling dkk.

    NPJ Precis Oncol · 2025 · Inggris · PubMed Central

    Anaplastic thyroid carcinoma (ATC) is an aggressive cancer that requirements rapid diagnosis and multimodal treatment. Next-generation sequencing (NGS) aids in personalized therapies and improved trial enrollment. The role of liquid-based NGS in ATC remains unclear. This study analyzed ATC samples…

  14. Artikel Jurnal Teks lengkap

    Comprehensive assessment of pretreatment sarcopenia impacts on patients with EGFR ‐mutated NSCLC treated with afatinib

    Wu, Chen‐Te; Hsu, Ping‐Chih; Chang, John Wen‐Cheng dkk.

    Thorac Cancer · 2023 · Inggris · PubMed Central

    BACKGROUND: This study aimed to comprehensively evaluate the efficacy and toxicity of afatinib in patients with sarcopenia, an important prognostic factor for treatment efficacy and toxicity in patients with cancer. METHODS: The clinical features of patients with advanced NSCLC treated with…

  15. Artikel Jurnal Teks lengkap

    Impact of T790M Mutation Status on Later-Line Osimertinib Treatment in Non-Small Cell Lung Cancer Patients

    Tang, Yan-Jei; Chang, John Wen-Cheng; Chang, Ching-Fu dkk.

    Cancers (Basel) · 2022 · Inggris · PubMed Central

    …advanced NSCLC treated with osimertinib following frontline EGFR-TKIs at Chang Gung Memorial Hospital from 2014 to 2018 were retrospectively reviewed. T790M mutations were detected using tissue sequencing and/or liquid biopsy. Results: A total of 172 EGFR-mutated NSCLC patients treated with…

  16. Artikel Jurnal Teks lengkap

    Prognostic Value of Lymph Node-To-Primary Tumor Standardized Uptake Value Ratio in Esophageal Squamous Cell Carcinoma Treated with Definitive Chemoradiotherapy

    Lin, Chia-Hsin; Hung, Tsung-Min; Chang, Yu-Chuan dkk.

    Cancers (Basel) · 2020 · Inggris · PubMed Central

    We aimed to investigate the prognostic value of the relative maximum standardized uptake value (SUV) of metastatic lymph node (LN) compared with that of primary tumor (SUV(LN)/SUV(Tumor)) based on a pretreatment [(18)F]-FDG PET/CT scan in patients with clinically node-positive esophageal squamous…

  17. Artikel Jurnal Teks lengkap

    Baseline and changes in inflammatory parameters for patients with EGFR ‐mutated NSCLC treated with afatinib

    Chang, Zi‐Ting; Hsu, Ping‐Chih; Ko, How‐Wen dkk.

    Thorac Cancer · 2025 · Inggris · PubMed Central

    BACKGROUND: This study investigated the relationship between inflammatory biomarkers (lymphocyte ratio [NLR], monocyte‐to‐lymphocyte ratio [MLR], and platelet‐to‐lymphocyte ratio [PLR]) and the treatment outcomes of patients with non‐small cell lung cancer (NSCLC) treated with afatinib. METHODS…

  18. Artikel Jurnal Teks lengkap

    Validation and application of a prognostic model for patients with advanced pancreatic cancer receiving palliative chemotherapy

    Huang, Pei‐Wei; Chang, Ching‐Fu; Hung, Chia‐Yen dkk.

    Cancer Med · 2019 · Inggris · PubMed Central

    BACKGROUND: We previously developed a robust prognostic model (GS model) to predict the survival outcome of patients with advanced pancreatic cancer (APC) receiving palliative chemotherapy with gemcitabine plus S‐1 (GS). This study aimed to validate the application of the GS model in APC patients…

  19. Artikel Jurnal Teks lengkap

    Comparative effectiveness and safety of enzalutamide versus abiraterone in patients with metastatic castration-resistant prostate cancer: a nationwide registry-based cohort study from Taiwan

    Huang, Wen-Kuan; Su, Po-Jung; Chen, Chun-Chi dkk.

    J Cancer Res Clin Oncol · 2025 · Inggris · PubMed Central

    PURPOSE: The real-world effectiveness and safety of abiraterone or enzalutamide in the Asian population with metastatic castration-resistant prostate cancer (mCRPC) remains unclear. METHODS: Using the Taiwan National Health Insurance Research Database, we identified a cohort of 3056 patients…

  20. Artikel Jurnal Teks lengkap

    Generation and validation of a predictive model for estimating survival among patients with EGFR-mutant non-small cell lung cancer

    Lin, Chien-Yu; Chou, Yun-Tse; Su, Po-Lan dkk.

    Am J Cancer Res · 2023 · Inggris · PubMed Central

    Although epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have become the standard therapy for patients with EGFR-mutant non-small cell lung cancer (NSCLC), treatment outcomes vary significantly. Previous studies have indicated that concurrent mutations may compromise the…